ProACT Adjustable Continence Therapy for Men
Uromedica, Inc. · Decision date Oct 3, 2025
What did the FDA approve?
FDA records P130018/S004 as a supplement to PMA P130018, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Oct 3, 2025.
FDA approval order statement
Approval of the modifications to the study protocol including expansion of the study to 10-14 study sites and modifications to the Informed Consent Form for the post-approval study.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Oct 3, 2025
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P130018/S004
- Regulatory pathway
- PMA supplement
- Applicant
- Uromedica, Inc.
- Product code
- EZY
- Decision code
- APPR
- Decision date
- Oct 3, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Device, incontinence, mechanical/hydraulic.
- Applicant
- Uromedica, Inc.
- Product code
- EZY
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P130018/S004 received
Application receipt date recorded by FDA.
P130018/S004 · FDA decision
Normal 180 Day Track No User Fee
P130018/S005 · Related supplement
ProACT Adjustable Continence Therapy for Men
P130018/S006 · Related supplement
ProACT Adjustable Continence Therapy for Men
Timeline entries are records held by MedtechLedger for P130018. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P130018
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ProACT Adjustable Continence Therapy for MenP130018/S005 | Uromedica, Inc. | PMA supplement | Jan 28, 2026 | FDA |
ProACT Adjustable Continence Therapy for MenP130018/S006 | Uromedica, Inc. | PMA supplement | Feb 11, 2026 | FDA |
Explore the linked device profile
Other records with product code EZY
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
AMS 800 Artificial Urinary Sphincter (AUS)P000053/S142 | Boston Scientific Corp | PMA supplement | Sep 14, 2026 | FDA |
AMS 800 Artificial Urinary Sphincter (AUS)P000053/S141 | Boston Scientific Corp | PMA supplement | Feb 25, 2026 | FDA |
| Boston Scientific Corp | PMA approval | Jun 14, 2001 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Uromedica, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1840 Berkshire Ln. N., Plymouth, MN, 55441
Sources and methodology
- Original FDA record: P130018/S004
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



